Immuneering flags new press release on atebimetinib preclinical study publication in Cancer Research
IMRX•Publication on atebimetinib preclinical study
Immuneering disclosed a Cancer Research publication on atebimetinib showing broad, durable preclinical activity across RAS- and RAF-mutant tumor models.
Head-to-head in vivo studies showed deeper, more durable tumor growth inhibition than binimetinib, with favorable tolerability in preclinical models.
